Seattle Genetics is a research institution that studies and packages its drugs in human antibodies. The antibody provides a certain toxic burden into the cancer cells to destroy it from the inside so as not to be able to function appropriately. Seattle Genetics is ranked as the biggest biotech in Washington, DC.
The institute has invested a lot in research and marketing its products to the public. Seattle Genetics has grown over the years hence seeking to recruit over 200 employees this year. Adcetris is a drug that has nourished and was introduced by Seattle Genetics. The drug main purpose is to treat the cancer of the lymph system that usually spreads to organs of the body.
Seattle Genetics had to come up with a new strategy on how they could raise finances to establish a new drug. Through the assistance and guidance of Takeda, they opened an office in Switzerland so as to continue improving their marketing worldwide. During 2016, Seattle had made sales of 418$ million raising the sales by 46% from 2014 under the leadership of Clay Siegall.
Seattle Genetics have involved themselves in four drugs that are to cure certain diseases. They include adcetris and AML, which is used to treat blood cancer. 22ME is also another drug which is under progress, it will be used to treat bladder cancer. Lastly, it’s the LIV1 drug which will be used to cure breast cancer.
Dr. Clay Siegall is the CEO, President and the co- founder of Seattle Genetics. He formed the institute in 1998. Through his management, Seattle was able to build an antibody based cancer therapies such as adcetris which was approved by the U.S Food and Drug Administration in 2011.
Dr. Clay is also a member of Board of the Ultragenyx which deals with the patients who suffers from ultra-rare diseases. Besides being the CEO of Seattle, he is also the director of Alder BioPharmaceuticals Inc. and Mirna Therapeutics Inc, both are private biotechnology companies.
Dr. Clay has a degree in Zoology from the University of Maryland and a Ph.D. in Genetics acquired from George Washington University. He started his career in National Institute of Health from 1988 to 1991. He later worked for Bristol Squibb Research Institute from 1991 to 1997. Clay is also a writer as he guides people on his articles and blogs, he has more than 70 publications and holds 15 patents.